Sino Biopharmaceutical Ltd (1177.HK)
10.78HKD
23 Aug 2019
HK$0.22 (+2.08%)
HK$10.56
HK$10.56
HK$10.96
HK$10.32
48,187,801
49,300,023
HK$10.96
HK$4.53
Latest Key Developments (Source: Significant Developments)
Sino Biopharmaceutical Says "Imatinib Mesylate Capsules" Passed Consistency Evaluation
Aug 1 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC APPROVED PASSING OF CONSISTENCY EVALUATION FOR "IMATINIB MESYLATE CAPSULES". Full Article
Sino Biopharmaceutical Announces Drug Registration Approval For Its Anti-Infective Drug
July 16 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"MOXIFLOXACIN HYDROCHLORIDE INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION. Full Article
Sino Biopharmaceutical Says Anlotinib Hydrochloride Capsules Obtained Approval For New Indication
July 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANLOTINIB HYDROCHLORIDE CAPSULES GOT APPROVAL FOR DRUG REGISTRATION FOR NEW INDICATION FOR TREATMENT OF "SOFT TISSUE SARCOMA".APPROVAL FOR DRUG REGISTRATION GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC. Full Article
Sino Biopharmaceutical Says Unit's Drug Approved For Drug Registration
July 4 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT'S ANTITHROMBOTIC DRUG "TICAGRELOR TABLET" APPROVED FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION. Full Article
Sino Biopharmaceutical Says "Tadalafil Tablet" Obtains Approval For Drug Registration
July 3 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::SINO BIOPHARMACEUTICAL LTD SAYS "TADALAFIL TABLET" OBTAINS APPROVAL FOR DRUG REGISTRATION.APPROVAL OBTAINED FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA. Full Article
Sino Biopharmaceutical Says Unit's Tenofovir Tablet Got EU Marketing Authorization
May 23 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TENOFOVIR DISOPROXIL FUMARATE TABLET DEVELOPED BY UNIT HAS OBTAINED MARKETING AUTHORIZATION ISSUED BY EUROPEAN UNION. Full Article
Sino Biopharmaceutical Posts Qtrly Underlying Profit Attributable RMB976.38 Mln
May 21 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::QTRLY REVENUE RMB6,208.03 MILLION, AN INCREASE OF ABOUT 33.4%.QTRLY UNDERLYING PROFIT ATTRIBUTABLE RMB976.38 MILLION, UP 22.4%.BOARD HAS DECLARED PAYMENT OF A QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE FOR THREE MONTHS ENDED 31 MARCH, 2019. Full Article
Sino Biopharmaceutical Says Drug Developed By Unit Gets Approval For Drug Registration
May 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::'AMBRISENTAN TABLET' DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC. Full Article
Sino Biopharmaceutical Says Drug Developed By Unit Received Approval For Registration
Jan 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::LINEZOLID & GLUCOSE INJECTION OF UNIT RECEIVED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION. Full Article
Sino Biopharmaceutical Updates On Price And Volume Movements Of Shares Of Co
Dec 6 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TWO PRODUCTS OF GROUP ARE SUCCESSFUL BIDDERS IN TENDER FOR CENTRALISED PROCUREMENT OF MEDICINES IN PILOT CITIES OF CHINA.SAVE AS DISCLOSED, NOT AWARE OF ANY REASONS FOR PRICE OR VOLUME MOVEMENTS OF SHARES OF CO. Full Article
Earnings vs. 
Estimates